Switch theme
Sign up to access all valuation multiples
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.
1998
1.9K+
LTM Revenue $737M
LTM EBITDA $136M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hepalink has a last 12-month revenue (LTM) of $737M and a last 12-month EBITDA of $136M.
In the most recent fiscal year, Hepalink achieved revenue of $733M and an EBITDA of $166M.
Hepalink expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hepalink valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $737M | XXX | $733M | XXX | XXX | XXX |
| Gross Profit | $737M | XXX | $244M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $136M | XXX | $166M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $94.4M | XXX | $103M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $85.1M | XXX | $89.8M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $171M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Hepalink's stock price is CNY 11 (or $1).
Hepalink has current market cap of CNY 15.7B (or $2.2B), and EV of CNY 16.2B (or $2.2B).
See Hepalink trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.2B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Hepalink has market cap of $2.2B and EV of $2.2B.
Hepalink's trades at 3.1x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Hepalink's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hepalink has a P/E ratio of 25.6x.
See valuation multiples for Hepalink and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 16.5x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 23.8x | XXX | 21.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 25.6x | XXX | 24.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 8.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHepalink's last 12 month revenue growth is 4%
Hepalink's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Hepalink's rule of 40 is -2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Hepalink's rule of X is 28% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Hepalink and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -2% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hepalink acquired XXX companies to date.
Last acquisition by Hepalink was XXXXXXXX, XXXXX XXXXX XXXXXX . Hepalink acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Hepalink founded? | Hepalink was founded in 1998. |
| Where is Hepalink headquartered? | Hepalink is headquartered in China. |
| How many employees does Hepalink have? | As of today, Hepalink has 1.9K+ employees. |
| Is Hepalink publicy listed? | Yes, Hepalink is a public company listed on SHE. |
| What is the stock symbol of Hepalink? | Hepalink trades under 002399 ticker. |
| When did Hepalink go public? | Hepalink went public in 2010. |
| Who are competitors of Hepalink? | Similar companies to Hepalink include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Hepalink? | Hepalink's current market cap is $2.2B |
| What is the current revenue of Hepalink? | Hepalink's last 12 months revenue is $737M. |
| What is the current revenue growth of Hepalink? | Hepalink revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Hepalink? | Current revenue multiple of Hepalink is 3.0x. |
| Is Hepalink profitable? | Yes, Hepalink is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Hepalink? | Hepalink's last 12 months EBITDA is $136M. |
| What is Hepalink's EBITDA margin? | Hepalink's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Hepalink? | Current EBITDA multiple of Hepalink is 16.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
